| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/08/2006 | WO2006010503A3 Rxr antagonists in the treatment of inflammatory diseases |
| 06/08/2006 | WO2006005578A3 Solid pharmaceutical composition comprising mirtazapine |
| 06/08/2006 | WO2006003479A3 New pseudopolymorph of desloratadine formed with carbon dioxide |
| 06/08/2006 | WO2006002887A8 Aqueous drink solution of indibulin (d-24851) and an organic acid |
| 06/08/2006 | WO2006002082A3 Carbazole formulations for the treatment of psoriasis and angiogenesis |
| 06/08/2006 | WO2006000903A3 Use of reboxetine for the treatment of pain |
| 06/08/2006 | WO2005123721A3 Amorphous and polymorphic forms of candesartan cilexetil |
| 06/08/2006 | WO2005120584A3 Radiolabeled arylsulfonyl compounds and uses thereof |
| 06/08/2006 | WO2005120563A3 Induction of an immune response against streptococcus pneumoniae polysaccharides |
| 06/08/2006 | WO2005120505A3 Tetrahydropyranyl cyclopentyl tetrahy-dropyridopyridine modulators of chemokine receptor activity |
| 06/08/2006 | WO2005120467A3 Dosage form containing the active ingredient cholylsarcosine |
| 06/08/2006 | WO2005118609A3 Small molecule stimulators of neuronal growth |
| 06/08/2006 | WO2005117968A3 Compositions and methods comprising an egfl7 antagonist for modulating vascular development |
| 06/08/2006 | WO2005111224A3 Water-soluble coenzyme q10 in inclusion complex with beta-cyclodextrin, process of preparing, and use thereof |
| 06/08/2006 | WO2005107771A3 Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer |
| 06/08/2006 | WO2005107464A3 Compounds and compositions as cathepsin s inhibitors |
| 06/08/2006 | WO2005105787A8 Rapid and robust 3d/3d registration technique |
| 06/08/2006 | WO2005099671A3 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| 06/08/2006 | WO2005082356A8 Use of beta-lapachone for the treatment of lung cancer |
| 06/08/2006 | WO2005082329B1 Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
| 06/08/2006 | WO2005076987A3 Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| 06/08/2006 | WO2005074599A3 Naphthalimide dosing by n-acetyl transferase genotyping |
| 06/08/2006 | WO2005070434A3 Treatment of aromatase inhibitor therapy-related osteoporosis |
| 06/08/2006 | WO2005062824A8 Anti-hypercholesterolemic compounds |
| 06/08/2006 | WO2005052121A3 Multivalent aptamers |
| 06/08/2006 | WO2005041900A3 Polyamine polymers |
| 06/08/2006 | WO2005037219A3 Disinfecting teat care compositions |
| 06/08/2006 | WO2005027996A3 Application of a therapeutic substance to a tissue location using an expandable medical device |
| 06/08/2006 | WO2005027833A3 Compound and method for treating androgen-independent prostate cancer |
| 06/08/2006 | WO2005020906A3 Intranasal opioid compositions |
| 06/08/2006 | WO2005014607A3 Antisense modulation of stearoyl-coa desaturase expression |
| 06/08/2006 | WO2005007106A3 Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage |
| 06/08/2006 | WO2005002527A3 Sirt1 modulation of adipogenesis and adipose function |
| 06/08/2006 | WO2004098676A3 Novel methods for administration of drugs and devices useful thereof |
| 06/08/2006 | WO2004073653A3 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
| 06/08/2006 | WO2004050020A3 Improved opioid pharmaceutical compositions |
| 06/08/2006 | WO2004014303A3 Method of applying hyaluronic acid to implant or graft to enhance lubricity and cellular density |
| 06/08/2006 | WO2003077857A3 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors |
| 06/08/2006 | WO2003057150A3 A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
| 06/08/2006 | US20060123495 Knockout mice and their use |
| 06/08/2006 | US20060122411 Chloride channel opener |
| 06/08/2006 | US20060122402 Manufacturing process for no-donating compounds such as no-donating diclofenac |
| 06/08/2006 | US20060122399 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| 06/08/2006 | US20060122397 Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain |
| 06/08/2006 | US20060122396 Into a difluorobenzoic acid, for producting quinolonecarboxylic acid serving as synthetic antibacterial agent, medicament, agricultural chemical, or veterinary drug; ionic liquid solvents |
| 06/08/2006 | US20060122392 Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient |
| 06/08/2006 | US20060122390 Boronic ester and acid compounds, synthesis and uses |
| 06/08/2006 | US20060122389 Pyrazolotriazines as kinase inhibitors |
| 06/08/2006 | US20060122387 Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells |
| 06/08/2006 | US20060122370 Specific binding agents of human angiopoietin-2 |
| 06/08/2006 | US20060122282 Method for treating skin disorders with xanthophylls |
| 06/08/2006 | US20060122281 Regimen for treating prostate tissue and surgical kit for use in the regimen |
| 06/08/2006 | US20060122280 Muscarinic agonists |
| 06/08/2006 | US20060122279 Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants |
| 06/08/2006 | US20060122278 di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene |
| 06/08/2006 | US20060122277 Topical nepafenac formulations |
| 06/08/2006 | US20060122276 Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections |
| 06/08/2006 | US20060122275 Agentfor reducing side effects of diclofenac |
| 06/08/2006 | US20060122274 Such as strontium glutamate, strontium malonate, and strontium alpha-ketoglutarate; osteoporosis, osteopenia |
| 06/08/2006 | US20060122273 Use for deferiprone |
| 06/08/2006 | US20060122272 Stable gabapentin compositions |
| 06/08/2006 | US20060122271 Stable gabapentin having pH within a controlled range |
| 06/08/2006 | US20060122270 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| 06/08/2006 | US20060122269 Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments |
| 06/08/2006 | US20060122268 Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders |
| 06/08/2006 | US20060122267 Compositions and methods for attenuating mitochondria-mediated cell injury |
| 06/08/2006 | US20060122266 Methods and compositions for malaria prophylaxis |
| 06/08/2006 | US20060122265 Process for modifying drug crystal formation |
| 06/08/2006 | US20060122264 Stem cell invasion inhibitor |
| 06/08/2006 | US20060122263 Central nervous system disorders;drug abuse; Parkinson's disease; antidepressants |
| 06/08/2006 | US20060122262 Use of equol for treating androgen mediated diseases |
| 06/08/2006 | US20060122261 [method of preparing labdane diterpene composition, preferably isoforskolin and deacetylforskolin from forskolin extract and their use for promoting lean body mass and other applications] |
| 06/08/2006 | US20060122260 Intermediates for aromatic polyketides as selective anticancer and antiviral agents |
| 06/08/2006 | US20060122259 Immobilization of taxane; anticancer, antitumor agents |
| 06/08/2006 | US20060122258 Taxane derivatives functionalized at the 14-position and a process for the preparation thereof |
| 06/08/2006 | US20060122257 Phenyl substituted carboxylic acids |
| 06/08/2006 | US20060122256 3-(3'-Acetylamino-biphenyl-4-yloxymethyl)-benzoic acid; antidiabetic; type 2 diabetes, insulin resistance, impaired glucose tolerance, obesity |
| 06/08/2006 | US20060122255 Derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide; for preparation of drugs |
| 06/08/2006 | US20060122254 Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor (PAI-1) |
| 06/08/2006 | US20060122253 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 06/08/2006 | US20060122252 Novel antituberculosis compounds, Hirsutellones A, B, and C |
| 06/08/2006 | US20060122251 and elevated intraocular pressure; e.g. 2-(7,8-Dihydro-[1,4]dioxino[2,3-g]indazol-1-yl)-1-methyl-ethylamine; serotonin 5-HT2 receptor agonists; chemical stability, sustained release |
| 06/08/2006 | US20060122250 does not require protection and deprotection of side chain functional groups; inter alia novel processes (incorporating Heck reactions) |
| 06/08/2006 | US20060122249 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 06/08/2006 | US20060122248 Methods of making 6-[(4,5-dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form |
| 06/08/2006 | US20060122247 Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition |
| 06/08/2006 | US20060122246 Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite |
| 06/08/2006 | US20060122245 Novel inhibitors of IMPDH enzyme |
| 06/08/2006 | US20060122244 Hypoglycemic agents; antidiabetic agentys; side effect reduction; cardiovascular disorders; anticancer agents |
| 06/08/2006 | US20060122243 Antiallergic |
| 06/08/2006 | US20060122242 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 06/08/2006 | US20060122241 Novel macrocycles for the treatment of cancer diseases |
| 06/08/2006 | US20060122240 Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof |
| 06/08/2006 | US20060122239 Lipid diseases; metabolism diosrders; antiproliferative agents |
| 06/08/2006 | US20060122238 Hydroxybenzoate salts of metanicotine compounds |
| 06/08/2006 | US20060122237 N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders |
| 06/08/2006 | US20060122236 Substituted biaryl-carboxylate derivatives |
| 06/08/2006 | US20060122235 Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide |
| 06/08/2006 | US20060122234 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 06/08/2006 | US20060122233 Rabeprazole calcium |